CClinicalTrials.gg
TerminatedNCT04053309ROSIUpdated May 19, 2021

Round Spermatid Injection Protocol

An observational study in Male Infertility Due to Azoospermia, sponsored by Reproductive Medicine Associates of New Jersey. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Reproductive Medicine Associates of New Jersey · Observational

Why this study was terminated
low enrollment
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3
Ages
18 Years and older
Sex
Male
01

Study summary

To evaluate embryology outcomes after application of a technique known as round spermatid injection (ROSI) into donor oocytes in a high-volume clinical infertility practice.

Read the detailed description

The objective of this study is to assess embryology outcomes after implementation of a laboratory protocol known as ROSI at a high-volume clinical infertility practice. All samples from enrolled male patients with azoospermia who proceed with surgical sperm extraction (TESE or microTESE) will be evaluated for the presence of round spermatids. These round spermatids will be used as research samples as opposed to being discarded.

The investigators aim to identify whether the injection of round spermatids into donor oocytes can lead to successful fertilization, progression to the blastocyst stage, and euploid status. Performance of ROSI using donor oocytes not intended for implantation will allow the investigators to gain valuable insight regarding fertilization and development without any direct risk to patients or future offspring. These embryos are being generated for research purposes only and will ultimately be destroyed after the study has concluded. The investigators will measure rates of isolation of round spermatids from surgical samples, fertilization rates using donor oocytes, rates of progression to the blastocyst stage, and rates of aneuploidy using the previously described technique of ROSI.

02

Conditions studied

  • Male Infertility Due to Azoospermia
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

At least 10 healthy oocyte donors and at least 10 male patients with a diagnosis of male factor infertility (undergoing TESE or microTESE) to participate in this study.

All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.

Eligibility criteria

Major Inclusion Criteria: The following are major inclusion criteria:

  1. A diagnosis of azoospermia after semen analysis.
  2. Indication to proceed with testicular sperm extraction (TESE or microTESE) based on a urologic evaluation.
  3. Presence of round spermatids from testicular sperm extraction (TESE or microTESE), irrespective of the presence or absence of mature spermatozoa.

Major Exclusion Criteria (must not meet any): The following are exclusion criteria:

  1. Under 18 years old
  2. All patients who do not voluntarily give their written consent for participation.
  3. Men who do not wish to use their gametes (round spermatids) for fertilization of donor oocytes for research purposes.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Males undergoing TESE or microTESE

    All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.

05

What researchers measure

Primary outcomes

  1. Euploid blastulation rate

    number of fertilized eggs progressing to the blastocyst stage of development which are euploid

    Time frame: 1-2 weeks

Secondary outcomes

  1. Fertilization Rate

    Number of mature eggs fertilized by round spermatids

    Time frame: 1 day post intracytoplasmic sperm injection procedure

  2. Prevalence of round spermatids in surgical sperm samples

    the number of round spermatids present after a TESE or microTESE procedure is performed

    Time frame: immediately after the TESE or microTESE

  3. Overall blastulation rate

    number of fertilized eggs progressing to the blastocyst stage of development

    Time frame: 1 week

  4. Aneuploidy rate

    the number of abnormal embryos after PGT-A

    Time frame: 2 weeks

06

Study locations

1 site
  • Reproductive Medicine Assoicates of New Jersey
    Basking Ridge, New Jersey 07920, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04053309
Lead sponsor
Reproductive Medicine Associates of New Jersey
Responsible party
Sponsor
First posted
Aug 12, 2019
Start date
Aug 16, 2019
Primary completion
Jan 8, 2021
Completion
Jan 8, 2021
Last update
May 19, 2021

Study contacts

Brent Hanson, MD
study director · Reproductive Medicine Associates of New Jersey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion